Patents by Inventor Jeff A. Zablocki

Jeff A. Zablocki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted alkyl piperazine derivatives
    Patent number: 6451798
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: September 17, 2002
    Assignee: CV Therapeutics, Inc.
    Inventors: Vaibhav Varkhedkar, Venkata P. Palle, Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn
  • ABCA-1 elevating compounds
    Publication number: 20020128266
    Abstract: The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.
    Type: Application
    Filed: December 4, 2001
    Publication date: September 12, 2002
    Inventors: Michael Campbell, Prabha N. Ibrahim, Jeff A. Zablocki, Richard Lawn
  • Thiophene A2A receptor agonists
    Patent number: 6440948
    Abstract: 2-(3-,4-(substituted)-5-alkylthienyl)adenosines and the 5′-uronic acid amide analogues thereof having the following formula: are disclosed herein. Additionally disclosed are medicinal methods of treatment wherein the adenosine A2A agonist activity of the noted compounds stimulates mammalian coronary vasodilation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: August 27, 2002
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • ABCA-1 elevating compounds
    Publication number: 20020111364
    Abstract: The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.
    Type: Application
    Filed: December 6, 2001
    Publication date: August 15, 2002
    Inventors: Michael Campbell, Prabha N. Ibrahim, Jeff A. Zablocki, Richard Lawn
  • ORALLY ACTIVE A1 ADENOSINE RECEPTOR AGONISTS
    Publication number: 20020091099
    Abstract: A substituted N6-oxa, thia, thioxa and azacycloalkyl substituted adenosine derivative and a method for using the composition as an A1 adenosine receptor agonist.
    Type: Application
    Filed: May 24, 1999
    Publication date: July 11, 2002
    Inventors: BRENT K. BLACKBURN, CHRIS MELVILLE, JEFF A. ZABLOCKI, VENKATA P. PALLE, EIFATIH O. ELZEIN, LISA WANG
  • ABCA-1 Elevating compounds
    Publication number: 20020082257
    Abstract: The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.
    Type: Application
    Filed: December 5, 2001
    Publication date: June 27, 2002
    Inventors: Prabha N. Ibrahim, Robert Jiang, Christopher Morrison, Kevin Shenk, Jeff A. Zablocki, Richard Lawn
  • N-pyrazole A2A adenosine receptor agonists
    Patent number: 6403567
    Abstract: 2-adenosine N-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: June 11, 2002
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • N6 heterocyclic 8-modified adenosine derivatives
    Publication number: 20020045595
    Abstract: N6 heterocyclic 8 modified adenosine derivatives that are selective, partial or full adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Application
    Filed: June 14, 2001
    Publication date: April 18, 2002
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Prabha N. Ibrahim, Luiz Belardenelli
  • N6 heterocyclic 5' modified adenosine derivatives
    Publication number: 20020037872
    Abstract: N6 heterocyclic 5′ modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Application
    Filed: June 8, 2001
    Publication date: March 28, 2002
    Applicant: CV Therapeutics, Inc.
    Inventors: Venkata P. Palle, Jeff A. Zablocki, Prabha N. Ibrahim, Vaibhav Varkhedkar, Luiz Belardinelli
  • Substituted piperazine compounds
    Publication number: 20020016463
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: February 7, 2002
    Inventors: Jeff Zablocki, Elfatih Elzein, Grigory Nudelman, Tim Marquart, Brent K. Blackburn, Venkata P. Palle
  • Substituted alkyl piperazine derivatives
    Publication number: 20010047001
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: November 29, 2001
    Inventors: Vaibhav Varkhedkar, Venkata P. Palle, Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn
  • Substituted piperazine compounds
    Publication number: 20010044541
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: November 22, 2001
    Inventors: Brent K. Blackburn, Jeff Zablocki, Elfatih Elzein, Grigory Nudelman
  • Aralkyl substituted piperazine compounds
    Publication number: 20010041704
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: November 15, 2001
    Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
  • Substituted alkylene diamine compounds
    Publication number: 20010036961
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: November 1, 2001
    Inventors: Elfatih Elzein, Jeff Zablocki, Tim Marquart
  • N6 heterocyclic 8-modified adenosine derivatives
    Patent number: 6294522
    Abstract: N6 heterocyclic 8 modified adenosine derivatives that are selective, partial or full adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: September 25, 2001
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Prabha N. Ibrahim, Luiz Belardenelli
  • C-pyrazole A2A receptor agonists
    Publication number: 20010018428
    Abstract: 2-adenosine C-pyrazole compositions having the following formula: 1
    Type: Application
    Filed: March 19, 2001
    Publication date: August 30, 2001
    Applicant: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Elfatih O. Elzein
  • N6 heterocyclic 5? modified adenosine derivatives
    Patent number: 6258793
    Abstract: N6 heterocyclic 5′ modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: July 10, 2001
    Assignee: CV Therapeutics, Inc.
    Inventors: Venkata P. Palle, Jeff A. Zablocki, Prabha N. Ibrahim, Vaibhav Varkhedkar, Luiz Belardenelli
  • C-pyrazole 2A A receptor agonists
    Patent number: 6214807
    Abstract: 2-adenosine C-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: April 10, 2001
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Elfatih O. Elzein
  • Propargyl phenyl ether A2A receptor agonists
    Patent number: 6180615
    Abstract: 2-adenosine propargyl phenyl ether compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: January 30, 2001
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Elfatih O. Elzein, Grigory Nudelman